دورية أكاديمية
أعرض في EDS

Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.

التفاصيل البيبلوغرافية
العنوان: Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis.
المؤلفون: Ho M; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Chen LJ; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Sin HPY; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Iu LPL; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Brelen M; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Ho ACH; Department of Paediatrics, Faculty of Medicine, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Lai TYY; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR., Young AL; Department of Ophthalmology & Visual Sciences, Prince of Wales Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR. youngla@ha.org.hk.; Department of Ophthalmology & Visual Sciences, Hong Kong Eye Hospital, the Chinese University of Hong Kong, Shatin, Hong Kong SAR. youngla@ha.org.hk.
المصدر: Journal of ophthalmic inflammation and infection [J Ophthalmic Inflamm Infect] 2019 Jul 31; Vol. 9 (1), pp. 14. Date of Electronic Publication: 2019 Jul 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 101553216 Publication Model: Electronic Cited Medium: Print ISSN: 1869-5760 (Print) Linking ISSN: 18695760 NLM ISO Abbreviation: J Ophthalmic Inflamm Infect Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer
مستخلص: Purpose: To report the clinical outcomes of adalimumab in treating refractory Behcet's disease (BD)-related uveitis in paediatric or adolescent patients.
Methods: Retrospective review of five paediatric or adolescent patients with BD-related uveitis with a minimum follow-up of 24 months.
Results: Disease quiescence was observed in 9 (90%) of 10 eyes at 12 months. The mean number of relapses per year per patient was 5 (range, 3-7) before initiation of adalimumab treatment. This was reduced to 0.2 relapse per patient per year among the five patients during the first 24 months after starting adalimumab treatment. At baseline, 5 eyes had active retinal vasculitis. Retinal vasculitis resolved in all cases (100%) after starting adalimumab. The mean time to complete resolution of inflammation was 3.4 weeks. The mean ± standard deviation logMAR best-corrected visual acuity was 0.711 ± 0.63 at baseline and improved to 0.172 ± 1.04 at 12 months (P < 0.001). None of the patients developed any adverse events associated with adalimumab treatment.
Conclusion: Adalimumab was effective in preventing irreversible sight-threatening BD-related uveitis in paediatric or adolescent patients. Adalimumab appears to be a promising treatment option for young patients with recalcitrant BD-related uveitis and has a favourable safety profile.
References: Br J Ophthalmol. 2002 Feb;86(2):140-3. (PMID: 11815335)
Mediators Inflamm. 2002 Apr;11(2):87-93. (PMID: 12061429)
Am J Ophthalmol. 2003 Dec;136(6):1114-9. (PMID: 14644223)
Ophthalmology. 2004 Mar;111(3):491-500; discussion 500. (PMID: 15019324)
Am J Ophthalmol. 2004 Sep;138(3):373-80. (PMID: 15364218)
Br J Ophthalmol. 2005 May;89(5):533-6. (PMID: 15834077)
Surv Ophthalmol. 2005 Jul-Aug;50(4):297-350. (PMID: 15967189)
Arthritis Rheum. 2005 Aug;52(8):2478-84. (PMID: 16052571)
Am J Ophthalmol. 2005 Sep;140(3):509-16. (PMID: 16196117)
Curr Opin Rheumatol. 2006 Jan;18(1):3-9. (PMID: 16344613)
Ophthalmology. 2006 May;113(5):860-4.e2. (PMID: 16545455)
Eye (Lond). 2007 Jun;21(6):824-5. (PMID: 16601736)
J Pediatr. 2006 Oct;149(4):572-5. (PMID: 17011337)
Br J Ophthalmol. 2007 Mar;91(3):319-24. (PMID: 17035274)
Rheumatology (Oxford). 2007 May;46(5):736-41. (PMID: 17403712)
Am J Ophthalmol. 2007 Dec;144(6):844-849. (PMID: 17953940)
Rheumatology (Oxford). 2008 Mar;47(3):339-44. (PMID: 18238789)
Ophthalmology. 2009 Aug;116(8):1544-51, 1551.e1. (PMID: 19651312)
Rheumatol Int. 2011 Feb;31(2):243-5. (PMID: 19816689)
Semin Arthritis Rheum. 2011 Aug;41(1):61-70. (PMID: 21168186)
JAMA. 2011 Apr 13;305(14):1460-8. (PMID: 21486979)
Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S54-7. (PMID: 21968237)
Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. (PMID: 22324897)
Ophthalmology. 2012 Aug;119(8):1575-81. (PMID: 22525047)
Rheumatology (Oxford). 2012 Oct;51(10):1825-31. (PMID: 22723596)
Br J Ophthalmol. 2013 Apr;97(4):481-6. (PMID: 23376607)
Pediatr Rheumatol Online J. 2013 Apr 15;11:16. (PMID: 23587261)
JAMA Ophthalmol. 2013 Nov;131(11):1405-12. (PMID: 24008391)
J AAPOS. 2013 Oct;17(5):456-9. (PMID: 24160962)
Ophthalmology. 2014 Mar;121(3):785-96.e3. (PMID: 24359625)
Trials. 2014 Jan 09;15:14. (PMID: 24405833)
Mediators Inflamm. 2013;2013:560632. (PMID: 24489444)
Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug;45(4):332-4. (PMID: 25037015)
J AAPOS. 2016 Apr;20(2):145-7. (PMID: 27079596)
Int Ophthalmol. 2017 Jun;37(3):719-725. (PMID: 27432171)
Ocul Immunol Inflamm. 2018;26(3):477-484. (PMID: 27775458)
N Engl J Med. 2017 Apr 27;376(17):1637-1646. (PMID: 28445659)
Curr Treatm Opt Rheumatol. 2017 Mar;3(1):1-16. (PMID: 28944162)
Br J Ophthalmol. 2018 Dec;102(12):1672-1678. (PMID: 29459430)
Ann Rheum Dis. 1984 Dec;43(6):783-9. (PMID: 6524980)
J Rheumatol. 1997 Jan;24(1):128-32. (PMID: 9002023)
Yonsei Med J. 1997 Dec;38(6):411-22. (PMID: 9509911)
J Pediatr. 1998 Apr;132(4):721-5. (PMID: 9580778)
فهرسة مساهمة: Keywords: Adalimumab; Behcet’s disease; Intraocular inflammation; Retinal vasculitis; Uveitis
تواريخ الأحداث: Date Created: 20190802 Latest Revision: 20201001
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6669227
DOI: 10.1186/s12348-019-0181-z
PMID: 31367810
قاعدة البيانات: MEDLINE
الوصف
تدمد:1869-5760
DOI:10.1186/s12348-019-0181-z